Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Anticancer Drugs. 2020 Jun;31(5):528-532. doi: 10.1097/CAD.0000000000000904.
Anticancer Drugs. 2020.
PMID: 32011361